To investigate the relationship between specific cancer types, treatment modalities, and the occurrence of herpes zoster (HZ) in cancer patients.
Key Findings:
89.89% of HZ patients developed the condition within 12 months after the first anticancer therapy (95% CI, p-value).
Hematologic cancers, particularly multiple myeloma, were associated with a significantly higher risk of HZ (OR = 2.41, 95% CI 1.11-5.24, P = 0.03).
The use of immune checkpoint inhibitors did not significantly increase the risk of HZ.
Interpretation:
Patients with hematologic malignancies are at a notably higher risk for developing herpes zoster, necessitating close monitoring and preventive measures for all cancer patients.
Limitations:
The study is retrospective and may be subject to biases inherent in such designs, including selection and information bias.
Data was collected from a single institution, which may limit generalizability.
Conclusion:
Hematologic cancer patients should be closely monitored for herpes zoster, and preventive measures should be considered to mitigate risk.
